Predictors and consequences of adherence to the treatment of pediatric patients with attention-deficit/hyperactivity disorder in Central Europe and East Asia
Open Access
- 1 September 2013
- journal article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 7, 987-995
Abstract
Purpose: To assess baseline predictors and consequences of medication non-adherence in the treatment of pediatric patients with attention-deficit/hyperactivity disorder (ADHD) from Central Europe and East Asia. Patients and methods: Data for this post-hoc analysis were taken from a 1-year prospective, observational study that included a total of 1,068 newly-diagnosed pediatric patients with ADHD symptoms from Central Europe and East Asia. Medication adherence during the week prior to each visit was assessed by treating physicians using a 5-point Likert scale, and then dichotomized into either adherent or non-adherent. Clinical severity was measured by the Clinical Global Impressions-ADHD-Severity (CGI-ADHD) scale and the Child Symptom Inventory-4 (CSI-4) Checklist. Health-Related Quality of Life (HRQoL) was measured using the Child Health and Illness Profile-Child Edition (CHIP-CE). Regression analyses were used to assess baseline predictors of overall adherence during follow-up, and the impact of time-varying adherence on subsequent outcomes: response (defined as a decrease of at least 1 point in CGI), changes in CGI-ADHD, CSI-4, and the five dimensions of CHIP-CE. Results: Of the 860 patients analyzed, 64.5% (71.6% in Central Europe and 55.5% in East Asia) were rated as adherent and 35.5% as non-adherent during follow-up. Being from East Asia was found to be a strong predictor of non-adherence. In East Asia, a family history of ADHD and parental emotional distress were associated with non-adherence, while having no other children living at home was associated with non-adherence in Central Europe as well as in the overall sample. Non-adherence was associated with poorer response and less improvement on CGI-ADHD and CSI-4, but not on CHIP-CE. Conclusion: Non-adherence to medication is common in the treatment of ADHD, particularly in East Asia. Non-adherence was associated with poorer response and less improvement in clinical severity. A limitation of this study is that medication adherence was assessed by the treating clinician using a single item question.Keywords
This publication has 34 references indexed in Scilit:
- ADHD medication use, adherence, persistence and cost among Texas Medicaid childrenCurrent Medical Research and Opinion, 2011
- A 12-Month Prospective, Observational Study of Treatment Regimen and Quality of Life Associated With ADHD in Central and Eastern Europe and Eastern AsiaJournal of Attention Disorders, 2010
- European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHDBMC Psychiatry, 2010
- Review of Medication Adherence in Children and Adults with ADHDPostgraduate Medicine, 2010
- Attention-Deficit/Hyperactivity Disorder Diagnosis, Co-Morbidities, Treatment Patterns, and Quality of Life in a Pediatric Population in Central and Eastern Europe and AsiaJournal of Child and Adolescent Psychopharmacology, 2009
- An Analysis of Patient Adherence to Treatment During a 1-Year, Open-label Study of OROS® Methylphenidate in Children With ADHDJournal of Attention Disorders, 2007
- Determinants of Adherence to Methylphenidate and the Impact of Poor Adherence on Maternal and Family MeasuresJournal of Child and Adolescent Psychopharmacology, 2006
- The effect of ADHD on the life of an individual, their family, and community from preschool to adult lifeArchives of Disease in Childhood, 2005
- The Parent Report Form of the CHIP–Child EditionMedical Care, 2004
- Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response StudyPediatrics, 2001